HIKMA PHARMACEUTICALS PLC - HKMPF STOCK NEWS

Hikma Pharmaceuticals PLC has publicly clarified that it has not engaged in any transaction with Opiant Pharmaceuticals, directly contradicting a prior announcement from PR Newswire. The earlier communication suggested Hikma entered into a commercialization and licensing agreement for OPNT003, Nasal Nalmefene, in Europe and the UK, which Hikma has confirmed is not the case. This statement helps to prevent any potential misinterpretations regarding Hikma's current partnerships and licensing activities.

On April 30, 2021, Hikma Pharmaceuticals announced FDA approval for KLOXXADO^TM (naloxone hydrochloride) nasal spray 8mg. This new treatment is designed for emergency use against opioid overdoses, featuring double the naloxone of Narcan^® (4mg). The rising opioid crisis necessitates innovative solutions, as overdose incidents surged, especially during the COVID-19 pandemic. Community surveys indicate a significant demand for higher naloxone doses, with 34% of Narcan reversals utilizing multiple doses. KLOXXADO^TM is expected to hit the market in late 2021.

Hikma Pharmaceuticals PLC has signed an exclusive license and distribution agreement with AFT Pharmaceuticals for Combogesic^® IV, a non-opioid intravenous pain relief medication. This agreement grants Hikma exclusive rights to market and distribute the product in the US, which is designed for post-operative use. AFT plans to file for FDA approval in the upcoming months. Hikma aims to expand its portfolio in non-opioid pain management, enhancing access to high-quality medicines for patients and healthcare providers in the US.

Hikma Pharmaceuticals has resumed the launch of its generic Advair Diskus in the US after receiving FDA approval for an amendment to its Abbreviated New Drug Application. The amendment was necessary to enhance packaging controls in compliance with new industry standards. The generic product is available in 100mcg/50mcg and 250mcg/50mcg doses, aimed at improving access to this critical medication for patients and healthcare providers in the US.

Hikma Pharmaceuticals announced a $4.06 million donation in medicines in 2020, up from $3.1 million in 2019. This includes immediate support to the Lebanese Ministry of Health after the Beirut explosion. The company established new partnerships with Dispensary of Hope, Direct Relief, Americares, Brother's Brother Foundation, and the National Children's Cancer Society. These collaborations aim to expand medicine donations to underprivileged communities affected by the COVID-19 pandemic.

Hikma Pharmaceuticals and Arecor Limited have expanded their collaboration with a new exclusive agreement to co-develop a ready-to-administer injectable medicine in the US. This builds on their previous partnership from January 2020. The product will utilize Arecor's Arestat™ technology and is expected to seek FDA approval via the 505(b)(2) pathway in 2023. The agreement includes royalty-based terms, with Hikma responsible for manufacturing and commercialization, while Arecor will receive upfront and milestone payments.

Hikma Pharmaceuticals announced that the US Court of Appeals upheld a ruling favoring its generic version of Vascepa, indicating no infringement on six Amarin patents. This decision follows FDA approval received in May 2020, setting the stage for the product's launch. Vascepa generated approximately $1.1 billion in US sales over the last year. Hikma aims to provide affordable access to this critical medication, reinforcing its commitment to improving health for patients in the US.

Hikma Pharmaceuticals has announced its participation in a CAD4.0 million Series A financing round for SeamlessMD, increasing the company's total funding to CAD7.4 million. SeamlessMD specializes in digital patient engagement and is utilized by several prominent health systems. Hikma Ventures aims to support the expansion of SeamlessMD's digital health solutions, particularly in the wake of increased demand due to COVID-19. SeamlessMD's platform is backed by significant clinical validation, demonstrating cost reductions and shorter hospital stays.